ArticleMarine drugs2017
Lobophorin K, a New Natural Product with Cytotoxic Activity Produced by Streptomyces sp. M-207 Associated with the Deep-Sea Coral Lophelia pertusa.
Abstract read
In one paragraph
Article in Marine drugs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Actinomycetota-Derived Metabolites in Pancreatic Cancer: Chemical Diversity, Metabolic Vulnerability, and Translational Barriers.Current oncology reports · 2026Review
- Metagenomics and its impact on environmental and therapeutic microbiology.Archives of microbiology · 2025Review
- Diversity of secondary metabolites from marine Streptomyces with potential anti-tubercular activity: a review.Archives of microbiology · 2025Review
- Antimicrobial Lobophorins from Endophytic StrainMolecules (Basel, Switzerland) · 2025Article
- Animal Microbiomes as a Source of Novel Antibiotic-Producing Strains.International journal of molecular sciences · 2023Review
- Bioactivity Screening and Genomic Analysis Reveals Deep-Sea Fish Microbiome Isolates as Sources of Novel Antimicrobials.Marine drugs · 2023Article
- The Isolation and Structure Elucidation of Spirotetronate Lobophorins A, B, and H8 fromMolecules (Basel, Switzerland) · 2023Article
- Antagonistic Potentiality of Actinomycete-Derived Extract with Anti-Biofilm, Antioxidant, and Cytotoxic Capabilities as a Natural Combating Strategy for Multidrug-Resistant ESKAPE Pathogens.Journal of microbiology and biotechnology · 2023Article
- The application and sustainable development of coral in traditional medicine and its chemical composition, pharmacology, toxicology, and clinical research.Frontiers in pharmacology · 2023Review
- Bacteria Associated with Benthic Invertebrates from Extreme Marine Environments: Promising but Underexplored Sources of Biotechnologically Relevant Molecules.Marine drugs · 2022Review
- Marine Actinomycetes Associated with Stony Corals: A Potential Hotspot for Specialized Metabolites.Microorganisms · 2022Review
- Promising bioactive compounds from the marine environment and their potential effects on various diseases.Journal, genetic engineering & biotechnology · 2022Review
- Cytotoxic compounds from marine actinomycetes: Sources, Structures and Bioactivity.Acta materia medica · 2022Article
- Lobophorin Producing EndophyticFrontiers in microbiology · 2022Article
- Natural Products from Actinomycetes Associated with Marine Organisms.Marine drugs · 2021Review
- A Treasure of Bioactive Compounds from the Deep Sea.Biomedicines · 2021Review
- Marine Bacterial Secondary Metabolites: A Treasure House for Structurally Unique and Effective Antimicrobial Compounds.Marine drugs · 2021Review
- Evaluation of antimicrobial and antiproliferative activities of Actinobacteria isolated from the saline lagoons of northwestern Peru.PloS one · 2021Article
- Bioactive Natural Products in Actinobacteria Isolated in Rainwater From Storm Clouds Transported by Western Winds in Spain.Frontiers in microbiology · 2021Article
- Bioactivity Potential of Marine Natural Products from Scleractinia-Associated Microbes and In Silico Anti-SARS-COV-2 Evaluation.Marine drugs · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Alfredo F BrañaDepartamento de Biología Funcional, Área de Microbiología, Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo, 33006 Oviedo, Spain. afb@uniovi.es.
Aida Sarmiento-VizcaínoDepartamento de Biología Funcional, Área de Microbiología, Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo, 33006 Oviedo, Spain. UO209983@uniovi.es.
Miguel OssetDepartamento de Biología Funcional, Área de Microbiología, Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo, 33006 Oviedo, Spain. UO21622@uniovi.es.
Ignacio Pérez-VictoriaFundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Avda. del Conocimiento 3, Parque Tecnológico de Ciencias de la Salud, E-18016 Granada, Spain. ignacio.perez-victoria@medinaandalucia.es.
Jesús MartínFundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Avda. del Conocimiento 3, Parque Tecnológico de Ciencias de la Salud, E-18016 Granada, Spain. jesus.martin@medinaandalucia.es.
Nuria de PedroFundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Avda. del Conocimiento 3, Parque Tecnológico de Ciencias de la Salud, E-18016 Granada, Spain. nuria.de.pedro@medinaandalucia.es.
Mercedes de la CruzFundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Avda. del Conocimiento 3, Parque Tecnológico de Ciencias de la Salud, E-18016 Granada, Spain. mercedes.delacruz@medinaandalucia.es.
Caridad DíazFundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Avda. del Conocimiento 3, Parque Tecnológico de Ciencias de la Salud, E-18016 Granada, Spain. caridad.diaz@medinaandalucia.es.
Francisca VicenteFundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Avda. del Conocimiento 3, Parque Tecnológico de Ciencias de la Salud, E-18016 Granada, Spain. francisca.vicente@medinaandalucia.es.
Fernando ReyesFundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Avda. del Conocimiento 3, Parque Tecnológico de Ciencias de la Salud, E-18016 Granada, Spain. fernando.reyes@medinaandalucia.es.
Luis A GarcíaDepartamento de Ingeniería Química y Tecnología del Medio Ambiente, Área de Ingeniería Química, Universidad de Oviedo, 33006 Oviedo, Spain. luisag@uniovi.es.
Gloria BlancoDepartamento de Biología Funcional, Área de Microbiología, Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo, 33006 Oviedo, Spain. gbb@uniovi.es.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present article describes the isolation of a new natural product of the lobophorin family, designated as lobophorin K (
Indexed as
AnimalsAnthozoaAntineoplastic AgentsCell Line, TumorCell SurvivalHumansMacrolidesMicrobial Sensitivity TestsMolecular StructurePhylogenyStreptomycesAntineoplastic Agentslobophorin KMacrolidesantitumorCantabrian Sea-derived actinobacterialobophorinsspirotetronate antibioticStreptomyces
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.